

XPH

State Street SPDR S&P Pharmaceuticals ETF

Analyst Report

This ETF is one of several options for investors looking to establish exposure to the U.S. pharmaceutical industry, a sub-sector of the health care space that can post big returns during periods of consolidation or as a result of advancements in medicine. Given this narrow focus, XPH probably doesn't belong in a long-term portfolio, though it may be useful for covering a corner of the domestic equity market that receives minimal weight in most portfolios. XPH is noteworthy because of the methodology employed by the underlying index; as an equal-weighted benchmark, this fund offers balanced exposure to the pharma sector, avoiding the potential pitfalls of cap-weighted benchmarks. This equal-weighted methodology distinguishes XPH from other pharma ETFs, such as PJP, PPH, and IHE.

ESG Themes and Scores

4.9/10

ESG Rate

15.25%

Global Percentile

9.68%

Peer Percentile

Performance Data

	XPH	ETF Database Category Average	Factset Segment Average
1 Month	-1.03%	3.82%	3.39%
3 Month	4.03%	2.50%	3.24%
YTD Return	3.47%	2.65%	6.57%
1 Year Return	41.80%	28.42%	40.92%
3 Year Return	14.11%	7.32%	14.84%
5 Year Return	4.04%	1.13%	7.79%

Top 5 Holdings

Symbol	Holding	% Assets
CORT	Corcept Therapeutics Incorporated.	4.05%
OGN	Organon & Co.	3.93%
AXSM	Axsome Therapeutics, Inc.	2.75%
LQDA	Liquidia Corporation	2.71%
DFTX	Definium Therapeutics, Inc.	2.38%

Vitals

Issuer	State Street
Brand	SPDR
Structure	ETF
Expense Ratio	0.35%
Inception	Jun 19, 2006
Index Tracked	S&P Pharmaceuticals Select Industry Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	North America
Region (Specific)	U.S.

FactSet Classifications

Segment	Equity: U.S. Pharmaceuticals
Category	Sector
Focus	Health Care
Niche	Pharmaceuticals
Strategy	Equal
Weighting	Equal

